Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Taladegib - Endeavor BioMedicines

Next Previous
X
Search
Drug Profile

Taladegib - Endeavor BioMedicines

Alternative Names: ENV 101; ENV-IPF-101; ENV-ONC-101; LY-2940680

Latest Information Update: 28 Nov 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company
  • Developer Eli Lilly and Company; Endeavor BioMedicines; Ignyta
  • Class Antifibrotics; Antineoplastics; Benzamides; Fluorobenzenes; Phthalazines; Piperidines; Pyrazoles; Small molecules
  • Mechanism of Action SMO protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cancer; Idiopathic pulmonary fibrosis; Solid tumours
  • Discontinued Adenocarcinoma; Basal cell cancer; Ovarian cancer; Small cell lung cancer

Most Recent Events

  • 15 Nov 2024 Endeavor Biomedicines initiates enrolment in phase-II WHISTLE-PF trial for Idiopathic pulmonary fibrosis ( in Australia (PO) (NCT06422884)
  • 19 May 2024 Endeavor Biomedicines plans phase-II WHISTLE-PF trial for Idiopathic pulmonary fibrosis and Pulmonary fibrosis in USA, Australia, Austria, Canada, Germany, Ireland, South Korea, Malaysia, Mexico, Switzerland and United Kingdom (In Children, In adolscents, In adults, In the elderly) (PO, Tablet) in September 2024 , (NCT06422884)
  • 17 May 2024 Efficacy and adverse events data from phase-IIa trial in Idiopathic pulmonary fibrosis presented at the 120th International Conference of the American Thoracic Society (ATS-2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top